A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
|
|
- Curtis Hodge
- 6 years ago
- Views:
Transcription
1 A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
2 Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular and macrovascular events will be reduced by: I. glucose control with a sulfonylurea (gliclazide-mr) based regimen targeting a hemoglobin A 1c of 6.5% of less II. Routine BP lowering with a fixed combination of an ACE inhibitor (perindopril) and a diuretic (indapamide)
3 Inclusion criteria Type 2 diabetes mellitus Age 55 years or older Additional risk of vascular event Age 65 years History of major macrovascular disease History of major microvascular disease First diagnosis of diabetes >10 years prior to entry Other major risk factor Any level of blood pressure Any level of glucose control but no definite indication for long-term insulin
4 Participant allocation Registration N = 12,877 Randomization N = 11,140 6 week run-in period with active fixed combination BP lowering glucose control glucose control glucose control glucose control and and and and Routine BP lowering Placebo Routine BP lowering Placebo (N = 2,783) (N = 2,788) (N = 2,786) (N = 2,783)
5 Primary study outcomes Macrovascular Non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular cause (including sudden death) Microvascular New of worsening nephropathy or diabetic eye disease Pre-specified joint and separate analyses of macrovascular and microvascular outcomes
6 Study population
7 Baseline characteristics I Characteristic glucose control and per/ind (N=2,783) glucose control and placebo (N=2,788) glucose control and per/ind (N=2,786) glucose control and placebo (N=2,783) Age (SD) 66 (6) 66 (6) 66 (6) 66 (6) Female, n (%) 1198 (43) 1181 (42) 1168 (42) 1188 (43) Duration of diabetes, years (SD) 8.0 (6.4) 7.8 (6.3) 8.0 (6.4) 8.0 (6.3) History of macrovascular disease, n (%) 896 (32.2) 898 (32.2) 902 (32.4) 894 (32.1) History of microvascular disease, n (%) 282 (10.1) 289 (10.4) 288 (10.3) 296 (10.6) Systolic BP, mmhg (SD) (22.1) (21.3) (21.6) (21.2)
8 Baseline characteristics II Characteristic glucose control and per/ind (N=2,783) glucose control and placebo (N=2,788) glucose control and per/ind (N=2,786) glucose control and placebo (N=2,783) Hemoglobin A 1c, % (SD) 7.5 (1.6) 7.5 (1.6) 7.6 (1.6) 7.5 (1.5) FBG, mmol/l (SD) 8.6 (2.8) 8.5 (2.7) 8.5 (2.8) 8.4 (2.8) FBG, mg/dl (SD) 155 (50) 153 (49) 153 (50) 151 (50) BP lowering drugs, n (%) 2089 (75.1) 2094 (75.1) 2077 (74.6) 2105 (75.6) Glucose lowering, n (%) 2543 (91.4) 2541 (91.1) 2539 (91.1) 2506 (90.1)
9 Timeline June 2001 January 2002 January 2003 January 2004 January 2005 January 2006 January 2007 January 2008 March 2003 Recruitment period Nov May 2007 Decision to extend study follow-up Blood pressure lowering comparison Blood glucose lowering comparison
10 Main results of the glucose control comparison
11 Randomized glucose lowering strategies control arm Gliclazide MR (sulfonylurea) in all participants Unrestricted additional therapy to achieve target HbA 1c 6.5% control arm Sulfonylurea other than Gliclazide MR Unrestricted additional therapy according to standard local guidelines All other treatment At discretion of treating physician
12 glucose control strategy More frequent visits Emphasis on lifestyle management Drug titration at physician s discretion based on HbA 1c and FBG levels: Maximize gliclazide MR dose Add other oral agents Add long-acting insulin Use multiple insulin injection therapy
13 ADVANCE Trial profile with type 2 diabetes registered 1737 withdrew during run-in randomized 5571 assigned intensive glucose control 5569 assigned standard glucose control 7 vital status unknown Scheduled end of follow-up: 5.0 years 4828 (87%) assessed at final visit 10 vital status unknown Scheduled end of follow-up: 5.0 years 4741 (85%) assessed at final visit
14 Glucose control drugs At randomization Sulfonylurea Metformin Thiazolidinediones Acarbose Glinides Insulin Randomized treatment (n=5571) 71% 61% 4% 9% 2% 1% (n=5569) 71% 60% 4% 8% 2% 1%
15 Glucose control drugs At end of follow-up Sulfonylurea Metformin Thiazolidinediones Acarbose Glinides Insulin Randomized treatment (n=4828) 91% 74% 17% 19% 1% 40% (n=4741) 59% 67% 11% 13% 3% 24%
16 Main results Hemoglobin A 1c
17 Hemoglobin A 1c Mean HbA 1c (%) Δ 0.67% (95% CI ); p<0.001 Mean HbA 1c at final visit 7.3 % 6.5% Follow-up (Months)
18 HbA 1c at end of follow-up >7.5% 7.1% to 7.5% 6.6% to 7.0% 6.0% to 6.5% <6.0% control control
19 Main results Primary outcomes
20 Combined primary outcomes Major macro or microvascular event Cumulative incidence (%) Relative risk reduction 10%: 95% CI: 2 to 18% p= Follow-up (months)
21 Primary outcomes Major macro or microvascular event Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Combined macro+micro % (2 to 18) Macrovascular % (-6 to 16) Microvascular % (3 to 23) Hazard ratio P=0.013 P=0.015
22 Major macrovascular events Cumulative incidence (%) Relative risk reduction 6%: 95% CI: -6 to 16% p= Follow-up (months)
23 Major macrovascular events Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Macrovascular % (-6 to 16) Non-fatal stroke % (-24 to 15) Non-fatal MI % (-23 to 22) Cardiovascular death % (-4 to 26) Hazard ratio
24 Major microvascular events Cumulative incidence (%) Relative risk reduction 14%: 95% CI: 3 to 23% p= Follow-up (months)
25 Major microvascular events Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Microvascular % (3 to 23) New or worsening retinopathy % (-10 to 18) New or worsening nephropathy % (7 to 34) Hazard ratio P=0.01 P=0.006
26 Main results Secondary outcomes
27 All-cause mortality Cumulative incidence (%) Relative risk reduction 7%: 95% CI -6 to 17% p= Follow-up (months)
28 Death Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95%CI) All deaths % (-6 to 17) Cardiovascular death % (-4 to 26) Non-cardiovascular death % (-20 to 16) Hazard ratio
29 Coronary and cerebrovascular events Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Total coronary events % (-10 to 13) Major coronary events % (-7 to 21) Total cerebrovascular events % (-26 to 7) Major cerebrovascular events % (-16 to 19) Hazard ratio Non-fatal MI or death from coronary heart disease Non-fatal stroke or death from cerebrovascular disease
30 Renal events Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Total renal events % (5 to 17) New microalbuminuria % (2 to 15) New or worsening nephropathy % (7 to 34) *** Hazard ratio P<0.001 P=0.02 ***P=0.006
31 Nephropathy Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) New or worsening nephropathy % (7 to 34) Macroalbuminuria % (15 to 43) Doubling of serum creatinine* % (-63 to 18) End-stage renal disease % (-8 to 62) Hazard ratio *to at least 200 μmol/l (2.3 mg/dl) P=0.006 P<0.001
32 Eye events Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Total eye events % (-5 to 5) New or worsening retinopathy % (-10 to 18) Visual deterioration % (-5 to 5) Hazard ratio
33 Heart failure, PVD and neuropathy Number (%) of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) All heart failure % (-14 to 21) All peripheral vascular disease % (-9 to 19) New or worsening neuropathy % (-10 to 2) Hazard ratio
34 Cognitive function and dementia Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Dementia % (-86 to 13) Cognitive decline % (-7 to 11) Hazard ratio
35 Effects in patient subgroups
36 Effects by age, sex, SBP & glucose control Combined primary endpoint Age (years) < % (1 to 25) % (-3 to 17) Sex Male % (0 to 19) Female % (-3 to 22) SBP (mmhg) < % (-4 to 21) % (1 to 20) HbA 1c (%) < % (-3 to 22) % (0 to 20) Fasting blood glucose (mmol/l) Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) < 7.9 (142 mg/dl) % (0 to 23) 7.9 (142 mg/dl) % (-2 to 18) All participants % (2 to 18) Hazard ratio Phomogeneity all >0.1
37 Effects by disease history & ancillary treatment Combined primary endpoint History of macrovascular disease Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) No % (4 to 23) Yes % (-10 to 16) History of microvascular disease No % (2 to 19) Yes % (-16 to 21) Treatment with any BP lowering drugs No % (-7 to 27) Yes % (1 to 18) Treatment with ACE inhibitors No % (3 to 24) Yes % (-7 to 16) Treatment with statins No % (1 to 19) Yes % (-6 to 24) Treatment with anti-platelet drugs No % (-2 to 20) Yes % (0 to 21) All participants % (2 to 18) Phomogeneity all >0.1 Hazard ratio
38 Effects by age, sex, SBP and glucose control Cardiovascular death Number of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Age (years) < % (-39 to 31) % (-3 to 30) Sex Male % (-8 to 28) Female % (-18 to 35) SBP (mmhg) < % (3 to 45) % (-19 to 22) HbA 1c (%) < % (-8 to 38) % (-12 to 27) Fasting blood glucose (mmol/l) < 7.9 (142 mg/dl) % (-3 to 38) 7.9 (142 mg/dl) % (-18 to 25) All participants % (-4 to 26) Hazard ratio Phomogeneity all >0.1
39 Effects by age, sex, SBP and glucose control All cause mortality Number (%) of patients with event (n=5,571) (n=5,569) Relative risk reduction (95% CI) Age (years) < % (-20 to 28) % (-8 to 18) Sex Male % (-13 to 16) Female % (-6 to 32) SBP (mmhg) < % (-1 to 33) % (-17 to 14) HbA 1c (%) < % (-17 to 20) % (-7 to 22) Fasting blood glucose (mmol/l) < 7.9 (142 mg/dl) % (-2 to 28) 7.9 (142 mg/dl) % (-19 to 15) All participants % (-6 to 17) Hazard ratio Phomogeneity all >0.1
40 Hypoglycemia
41 Rates of hypoglycemia Minor and severe Events per 100 patient years %* Minor hypoglycemia control control +87%* Severe hypoglycemia *p<0.001
42 Comparative rates of severe hypoglycemia 2.0% 1.6% 1.2% 0.8% 0.4% Proportion of patients with at least one event each year 0.0% control control UKPDS ADVANCE
43 Body weight
44 Difference in body weight Difference 0.75kg (0.56, 0.94) 1.65lbs (1.23, 2.07), p< Weight (kg) Follow-up (months)
45 Conclusions on safety glucose lowering was safe No excess mortality No weight gain No excess of serious sequelae from hypoglycemia Death or disability Cognitive function
46 Summary effects on main efficacy outcomes glucose control resulted in: 10% reduction in combined primary outcome 14% reduction in microvascular events 21% reduction in nephropathy No significant effects on macrovascular events No significant effects on all-cause or cardiovascular mortality Consistent treatment effects in patient subgroups
ADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationThis regimen can safely be recommended for patients with type 2 diabetes in all of these regions. Diabetes Care 34: , 2011
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Does Glycemic Control Offer Similar Benefits Among Patients With Diabetes in Different Regions of the World? Results
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationComputer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting
VALUE IN HEALTH 16 (2013) 670 685 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationCardiovascular outcomes in type 2 diabetes: the impact of preventative therapies
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: The Year in Diabetes and Obesity Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies Sophia
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationCardiovascular Diabetology. Open Access ORIGINAL INVESTIGATION. C. R. L. Cardoso 1, N. C. Leite 1, C. B. M. Moram 2 and G. F.
https://doi.org/10.1186/s12933-018-0677-0 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Long term visit to visit glycemic variability as predictor of micro and macrovascular complications
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationDIABETES AND METABOLIC SYNDROME
TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 48,508 20,091 41.4% 61.1 4.3 4/7 (57.1%) HR PROactive (Dormandy et al 61
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationReview. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction
Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More information1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial?
Jeff D. Williamson, MD, MHS Chief, Geriatric Medicine Sticht Center on Aging 1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial? 2. Are
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationVascular complications
Vascular complications December 8, 2018 Faculty Disclosure Faculty: Kim Connelly, MBBS, PhD, FRACP Associate Professor of Medicine, University of Toronto Cardiologist, St. Michael s Hospital Relationships
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More informationESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationLong-Term Care Updates
Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationSanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes
PRESS RELEASE Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes Dublin, Ireland (15 June 2012) Sanofi presented results
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationNear-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE
Therapeutic Advances in Endocrinology and Metabolism Review Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE Patrick J. O Connor and Faramarz Ismail-Beigi
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationThe publication of the U.K. Prospective
D I A B E T E S A N D C A R D I O V A S C U L A R D I S E A S E A Summary of the ADVANCE Trial SIMON R. HELLER, DM, FRCP ON BEHALF OF THE ADVANCE COLLABORATIVE GROUP* The publication of the U.K. Prospective
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationDiabetes Control and Complications in Public Hospitals in Malaysia
ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,
More informationDiabetes in the Elderly 1, 2, 3
Diabetes in the Elderly 1, 2, 3 WF Mollentze Feb 2010 Diabetes in the elderly differs from diabetes in younger people Prevalence: o Diabetes increases with age affecting approximately 10% of people over
More informationCANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Diabetes Management Coutts S, Wein T (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2014 Heart and Stroke Foundation November 2014
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationSponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationLIRAGLUTIDE VS EXENATIDE IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA THERAPY IN TYPE 2 DIABETES MELLITUS THERAPY IN BULGARIA. A MODELLING STUDY.
LIRAGLUTIDE VS EXENATIDE IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA THERAPY IN TYPE 2 DIABETES MELLITUS THERAPY IN BULGARIA. A MODELLING STUDY. Petrova Guenka, Anna Ivanova, Marcin Czech, Vasil
More informationThe New Diabetes Standard of Care: More Than Just Glycemic Control. Copyright
CLINICAL Viewpoint The New Diabetes Standard of Care: More Than Just Glycemic Control Advancement in Diabetes Management: A Canadian Diabetes Steering Committee Report Copyright Not for Sale or Commercial
More informationDiabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationIndividualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus
1 Dissertation Title Page: Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus Qian Shi, MPH, PhD candidate Department of Global Health Management
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More informationAssociation of HbA 1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds
Diabetologia (0) :636 643 DOI 0.007/s00-0-404- ARTICLE Association of HbA c levels with vascular complications and death in patients with type diabetes: evidence of glycaemic thresholds S. Zoungas & J.
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ray K K, Seshasai S R K, Wijesuriya S,
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More informationEducational and behavioral interventions hitherto published
Treatment of High-Risk Patients with Diabetes: Motivation and Teaching Intervention: A Randomized, Prospective 8-Year Follow-Up Study Rita Rachmani, Inna Slavacheski, Maya Berla, Ronni Frommer-Shapira,
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More information